Lapatinib for breast cancer: a review of the current literature
Author:
Publisher
Informa Healthcare
Subject
Pharmacology (medical),General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1517/14740338.2011.533168
Reference67 articles.
1. Cancer Statistics, 2009
2. Emerging drugs to replace current leaders in first-line therapy for breast cancer
3. Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
4. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
5. Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Copper-Catalyzed Consecutive Ullmann, Decarboxylation, Oxidation, and Dehydration Reaction for Synthesis of Pyrrolo or Pyrido[1,2-a]imidazo[1,2-c]quinazolines;Organic Letters;2023-06-29
2. Inhibition of mutationally activated HER2;Chemical Biology & Drug Design;2022-08-27
3. Conformation-tunable ATP-competitive kinase inhibitors;Chemical Communications;2022
4. Discovery and Pharmacological Evaluation of STEAP4 as a Novel Target for HER2 Overexpressing Breast Cancer;Frontiers in Oncology;2021-03-26
5. Treatment of cancer cells with Lapatinib negatively regulates general translation and induces stress granules formation;PLOS ONE;2020-05-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3